JP5824050B2 - 置換イミダゾピリダジン類 - Google Patents

置換イミダゾピリダジン類 Download PDF

Info

Publication number
JP5824050B2
JP5824050B2 JP2013527575A JP2013527575A JP5824050B2 JP 5824050 B2 JP5824050 B2 JP 5824050B2 JP 2013527575 A JP2013527575 A JP 2013527575A JP 2013527575 A JP2013527575 A JP 2013527575A JP 5824050 B2 JP5824050 B2 JP 5824050B2
Authority
JP
Japan
Prior art keywords
alkyl
amino
imidazo
cyclopropyl
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013527575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537174A5 (OSRAM
JP2013537174A (ja
Inventor
ウルリッヒ・クラー
マルクス・コピッツ
ロルフ・ヤウテラット
ディルク・コーゼムント
ロルフ・ボールマン
フィリップ・リーナウ
ゲルハルト・ジーマイスター
アンツェ・マルグレート・ヴェングナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of JP2013537174A publication Critical patent/JP2013537174A/ja
Publication of JP2013537174A5 publication Critical patent/JP2013537174A5/ja
Application granted granted Critical
Publication of JP5824050B2 publication Critical patent/JP5824050B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Paper (AREA)
JP2013527575A 2010-09-10 2011-09-06 置換イミダゾピリダジン類 Expired - Fee Related JP5824050B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10176134 2010-09-10
EP10176134.4 2010-09-10
EP11075022 2011-02-04
EP11075022.1 2011-02-04
EP11170775 2011-06-21
EP11170775.8 2011-06-21
EP11170771.7 2011-06-21
EP11170771 2011-06-21
PCT/EP2011/065368 WO2012032031A1 (en) 2010-09-10 2011-09-06 Substituted imidazopyridazines

Publications (3)

Publication Number Publication Date
JP2013537174A JP2013537174A (ja) 2013-09-30
JP2013537174A5 JP2013537174A5 (OSRAM) 2014-10-09
JP5824050B2 true JP5824050B2 (ja) 2015-11-25

Family

ID=44545741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527575A Expired - Fee Related JP5824050B2 (ja) 2010-09-10 2011-09-06 置換イミダゾピリダジン類

Country Status (38)

Country Link
US (1) US9255100B2 (OSRAM)
EP (1) EP2614063B1 (OSRAM)
JP (1) JP5824050B2 (OSRAM)
KR (1) KR20140032337A (OSRAM)
CN (1) CN103370318B (OSRAM)
AP (1) AP3607A (OSRAM)
AR (1) AR082946A1 (OSRAM)
AU (1) AU2011298844B2 (OSRAM)
BR (1) BR112013005679A2 (OSRAM)
CA (1) CA2810755A1 (OSRAM)
CO (1) CO6720961A2 (OSRAM)
CR (1) CR20130102A (OSRAM)
CU (1) CU24187B1 (OSRAM)
CY (1) CY1117352T1 (OSRAM)
DK (1) DK2614063T3 (OSRAM)
DO (1) DOP2013000054A (OSRAM)
EA (1) EA023420B1 (OSRAM)
EC (1) ECSP13012752A (OSRAM)
ES (1) ES2568220T3 (OSRAM)
HR (1) HRP20160360T1 (OSRAM)
HU (1) HUE028771T2 (OSRAM)
IL (1) IL225058A (OSRAM)
MA (1) MA34516B1 (OSRAM)
ME (1) ME02389B (OSRAM)
MX (1) MX2013002713A (OSRAM)
MY (1) MY185139A (OSRAM)
NZ (1) NZ607904A (OSRAM)
PE (1) PE20131164A1 (OSRAM)
PH (1) PH12013500454A1 (OSRAM)
PL (1) PL2614063T3 (OSRAM)
RS (1) RS54661B1 (OSRAM)
SA (1) SA111320735B1 (OSRAM)
SG (1) SG188417A1 (OSRAM)
SI (1) SI2614063T1 (OSRAM)
TW (1) TWI541243B (OSRAM)
UY (1) UY33598A (OSRAM)
WO (1) WO2012032031A1 (OSRAM)
ZA (1) ZA201301756B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
AP2015008898A0 (en) 2013-06-11 2015-12-31 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
EP3007698A1 (en) * 2013-06-13 2016-04-20 Bayer Pharma Aktiengesellschaft Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物,其制备方法及用途
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
JP6506313B2 (ja) * 2014-02-21 2019-04-24 フロスト バイオロジック,インコーポレーテッド 癌及び増殖性疾患の治療のための抗有糸分裂性アミド
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
JP6993233B2 (ja) 2015-04-17 2022-01-13 ネザーランズ トランスレーショナル リサーチ センター ビー.ブイ. Ttk阻害剤化学療法の為の予後バイオマーカー
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
JP6778749B2 (ja) * 2015-12-04 2020-11-04 エクソンモービル リサーチ アンド エンジニアリング カンパニーExxon Research And Engineering Company Emm−28、新規合成結晶性材料、その製造および使用
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
KR102700233B1 (ko) 2016-07-18 2024-08-28 유니버시티 헬스 네트워크 고체 형태의 ttk 억제제
EP3609547B1 (en) * 2017-04-11 2021-10-06 Straumann Holding AG Dental implant
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
HUE068695T2 (hu) 2018-05-08 2025-01-28 Nippon Shinyaku Co Ltd Azabenzimidazol vegyületek és gyógyszerek
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
KR20240107189A (ko) * 2021-12-15 2024-07-08 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물
EP4651948A1 (en) * 2023-01-19 2025-11-26 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333302A (en) 1996-08-28 2000-08-25 Pfizer Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
AR045697A1 (es) 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
EP1713784A1 (en) 2004-02-12 2006-10-25 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
BRPI0618520A2 (pt) * 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008130951A1 (en) * 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
US20110046127A1 (en) 2007-11-08 2011-02-24 Paolo Pevarello Imidazopyridazines for Use as Protein Kinase Inhibitors
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010124826A1 (en) 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
ES2551407T3 (es) 2010-03-18 2015-11-18 Bayer Intellectual Property Gmbh Imidazopirazinas
EP2576560B1 (en) 2010-06-01 2015-09-30 Bayer Intellectual Property GmbH Substituted imidazopyrazines
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080229A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
WO2012080234A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821837A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821827A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Also Published As

Publication number Publication date
HRP20160360T1 (hr) 2016-05-06
DOP2013000054A (es) 2013-07-31
SI2614063T1 (sl) 2016-05-31
ECSP13012752A (es) 2014-01-31
MX2013002713A (es) 2013-05-22
CO6720961A2 (es) 2013-07-31
EP2614063B1 (en) 2016-01-13
PH12013500454A1 (en) 2013-04-29
IL225058A (en) 2017-03-30
NZ607904A (en) 2015-02-27
HUE028771T2 (en) 2016-12-28
AU2011298844A1 (en) 2013-03-28
AP2013006790A0 (en) 2013-04-30
EA201390339A1 (ru) 2013-09-30
MA34516B1 (fr) 2013-09-02
ME02389B (me) 2016-09-20
CN103370318B (zh) 2016-04-20
SG188417A1 (en) 2013-04-30
MY185139A (en) 2021-04-30
UY33598A (es) 2012-04-30
EP2614063A1 (en) 2013-07-17
PL2614063T3 (pl) 2016-06-30
CA2810755A1 (en) 2012-03-15
TWI541243B (zh) 2016-07-11
US9255100B2 (en) 2016-02-09
AR082946A1 (es) 2013-01-23
CR20130102A (es) 2013-04-17
DK2614063T3 (en) 2016-04-18
US20130338133A1 (en) 2013-12-19
SA111320735B1 (ar) 2015-10-21
RS54661B1 (sr) 2016-08-31
CU20130033A7 (es) 2013-08-29
JP2013537174A (ja) 2013-09-30
CN103370318A (zh) 2013-10-23
CU24187B1 (es) 2016-07-29
WO2012032031A1 (en) 2012-03-15
TW201211049A (en) 2012-03-16
PE20131164A1 (es) 2013-10-30
KR20140032337A (ko) 2014-03-14
ES2568220T3 (es) 2016-04-28
HK1187623A1 (zh) 2014-04-11
AP3607A (en) 2016-02-26
ZA201301756B (en) 2016-06-29
BR112013005679A2 (pt) 2016-05-03
EA023420B1 (ru) 2016-06-30
CY1117352T1 (el) 2017-04-26
AU2011298844B2 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
JP5824050B2 (ja) 置換イミダゾピリダジン類
JP6174586B2 (ja) 置換イミダゾピリダジン
JP6174583B2 (ja) アミノ置換イミダゾピリダジン
JP5989091B2 (ja) トリアゾロピリジン類
JP5833644B2 (ja) 置換トリアゾロピリジン
JP5951750B2 (ja) 置換イミダゾピリジン類およびその中間体
JP6001049B2 (ja) Mps−1キナーゼ阻害剤としての置換ベンズイミダゾール類
EP2651950A1 (en) 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2013545778A (ja) 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン
JP2013545779A (ja) 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン
JP2015500309A (ja) アミノ置換イミダゾピリダジン
JP2014503521A (ja) 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、イミダゾピラジン類
JP5964853B2 (ja) 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、6−チオ置換イミダゾピラジン類
JP2017503809A (ja) アミド置換イミダゾピリダジン
JP6166289B2 (ja) 置換イミダゾピリダジン
HK1187623B (en) Substituted imidazopyridazines
TW201336849A (zh) 經取代咪唑并嗒□

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140825

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150226

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151008

R150 Certificate of patent or registration of utility model

Ref document number: 5824050

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees